. 2020 Jul 10;27(9):2251–2260. doi: 10.1016/j.sjbs.2020.07.011

Table 3.

Effect of Doxorubicin (DOX) and different treatments of AHE on urine creatinine, creatinine clearance, albumin and proteinuria.

Treatment (mg/kg)	Creatinine (mg/dl)	Creatinine clearance (ml/min)	Albumin (mg/dl)	Urinary Protein (mg/dl)
Control	0.4033 ± 0.055^b	0.8252 ± 0.064^b**	7.337 ± 0.171^b	23.29 ± 0.761^b
DOX	1.387 ± 0.019^a	0.4002 ± 0.043^a**	15.83 ± 0.418^a	54.35 ± 0.805^a
AHE alone	0.4007 ± 0.055^b	0.8265 ± 0.065^b**	7.280 ± 0.141^b	23.29 ± 0.025^b
DOX + AHE (200)	0.900 ± 0.029^a,b,d	0.5990 ± 0.055	11.57 ± 0.348^a,b,d	34.50 ± 0.433^a,b,d**
DOX + AHE (400)	0.5077 ± 0.037^b,c	0.7575 ± 0.075^b*	8.817 ± 0.235^a*,b,c	27.60 ± 0.432^a,b,c
DOX + Sily	0.497 ± 0.035^b	0.7584 ± 0.071^b*	8.833 ± 0.167^a*,b	27.17 ± 0.029^a**,b

Values expressed as mean ± SEM. a: Significance at p < 0.0001 Vs. control group, b: Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^{*, **}: Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin.